Inhibikase Therapeutics Inc
NASDAQ:IKT

Watchlist Manager
Inhibikase Therapeutics Inc Logo
Inhibikase Therapeutics Inc
NASDAQ:IKT
Watchlist
Price: 1.77 USD -10.61% Market Closed
Market Cap: 131.6m USD
Section:
Relative Value
Relative Value
Valuation Multiples
Multiples Across Competitors
See Also

Relative Value

IKT doesn't have a meaningful market cap.

There is not enough data to reliably calculate the relative value of IKT.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

IKT Relative Value
Base Case
Not Available
Worst Case
Base Case
Best Case

Valuation Multiples

N/A
P/S
P/S
Price to Sales
N/A
vs History
vs Industry
21
Median 3Y
51.1
Median 5Y
30.2
Industry
7.6
More Details
Negative
P/E
P/E
Price to Earnings
N/A
vs History
vs Industry
Median 3Y
-1
Median 5Y
-1.2
Industry
24.2
Forward
-4.1
More Details
Negative
P/OCF
P/OCF
Price to OCF
N/A
vs History
vs Industry
Median 3Y
-1.1
Median 5Y
-1.3
Industry
20.3
More Details
Negative
P/FCFE
P/FCFE
Price to FCFE
N/A
vs History
vs Industry
Median 3Y
-1
Median 5Y
-1.3
Industry
22.9
More Details
1.5
P/B
P/B
Price to Book Value
1.5
vs History
26
vs Industry
50
Median 3Y
0.9
Median 5Y
1.1
Industry
2.9
More Details
N/A
EV/S
EV/S
Enterprise Value to Sales
N/A
vs History
vs Industry
52
Median 3Y
-37.6
Median 5Y
-20.7
Industry
7.9
More Details
N/A
EV/GP
EV/GP
Enterprise Value to Gross Profit
N/A
vs History
vs Industry
Median 3Y
0
Median 5Y
0
Industry
10
More Details
Negative
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
N/A
vs History
vs Industry
30
Median 3Y
0.1
Median 5Y
-0.1
Industry
5.1
More Details
Negative
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
N/A
vs History
vs Industry
28
Median 3Y
0.1
Median 5Y
-0.1
Industry
5.1
Forward
-1
More Details
Negative
EV/OCF
EV/OCF
Enterprise Value to OCF
N/A
vs History
vs Industry
32
Median 3Y
0.1
Median 5Y
-0.1
Industry
5.7
More Details
Negative
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
N/A
vs History
vs Industry
28
Median 3Y
0.1
Median 5Y
-0.1
Industry
4.2
More Details
Negative
EV/IC
EV/IC
Enterprise Value to IC
N/A
vs History
vs Industry
7
Median 3Y
-8.9
Median 5Y
-6
Industry
5.2
More Details

Multiples Across Competitors

IKT Competitors Multiples
Inhibikase Therapeutics Inc Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
Market Cap P/S P/E EV/EBITDA EV/EBIT
US
Inhibikase Therapeutics Inc
NASDAQ:IKT
131.6m USD 0 -3.6 -1 -1
FR
Pharnext SCA
OTC:PNEXF
6T USD 33 706 744.2 -160 203.2 -194 537.7 -192 317.8
US
Abbvie Inc
NYSE:ABBV
336.1B USD 5.9 80.9 15.4 22.7
US
Cyclo Therapeutics Inc
NASDAQ:CYTH
325.9B USD 374 305.7 -13 141.6 -13 213.5 -13 207.5
US
Amgen Inc
NASDAQ:AMGN
164.8B USD 4.8 27.8 14.8 24.4
US
Gilead Sciences Inc
NASDAQ:GILD
144.7B USD 5 24.3 10.5 14.5
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
120.7B USD 10.9 -122 26 27.2
US
Epizyme Inc
F:EPE
94.1B EUR 2 090.1 -533.3 -580.7 -565.3
AU
CSL Ltd
ASX:CSL
129.7B AUD 5.6 31 19 23.7
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
60.9B USD 4.3 13.5 12.1 13.6
US
Seagen Inc
F:SGT
39.3B EUR 20.1 -61.7 -66.6 -60.1
P/S Multiple
Revenue Growth P/S to Growth
US
Inhibikase Therapeutics Inc
NASDAQ:IKT
Average P/S: 3 408 319.7
Not Available 		N/A N/A
FR
Pharnext SCA
OTC:PNEXF
33 706 744.2
N/A N/A
US
Abbvie Inc
NYSE:ABBV
5.9
8%
0.7
US
Cyclo Therapeutics Inc
NASDAQ:CYTH
374 305.7
140%
2 673.6
US
Amgen Inc
NASDAQ:AMGN
4.8
4%
1.2
US
Gilead Sciences Inc
NASDAQ:GILD
5
3%
1.7
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
10.9
10%
1.1
US
E
Epizyme Inc
F:EPE
2 090.1
N/A N/A
AU
CSL Ltd
ASX:CSL
5.6
7%
0.8
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
4.3
4%
1.1
US
S
Seagen Inc
F:SGT
20.1
30%
0.7
P/E Multiple
Earnings Growth PEG
US
Inhibikase Therapeutics Inc
NASDAQ:IKT
Average P/E: 35.5
Negative Multiple: -3.6 		N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -160 203.2 N/A N/A
US
Abbvie Inc
NYSE:ABBV
80.9
88%
0.9
US
Cyclo Therapeutics Inc
NASDAQ:CYTH
Negative Multiple: -13 141.6 N/A N/A
US
Amgen Inc
NASDAQ:AMGN
27.8
45%
0.6
US
Gilead Sciences Inc
NASDAQ:GILD
24.3
189%
0.1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Negative Multiple: -122 N/A N/A
US
E
Epizyme Inc
F:EPE
Negative Multiple: -533.3 N/A N/A
AU
CSL Ltd
ASX:CSL
31
16%
1.9
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
13.5
7%
1.9
US
S
Seagen Inc
F:SGT
Negative Multiple: -61.7 N/A N/A
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
US
Inhibikase Therapeutics Inc
NASDAQ:IKT
Average EV/EBITDA: 16.3
Negative Multiple: -1 		N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -194 537.7 N/A N/A
US
Abbvie Inc
NYSE:ABBV
15.4
13%
1.2
US
Cyclo Therapeutics Inc
NASDAQ:CYTH
Negative Multiple: -13 213.5 N/A N/A
US
Amgen Inc
NASDAQ:AMGN
14.8
17%
0.9
US
Gilead Sciences Inc
NASDAQ:GILD
10.5
6%
1.8
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
26
17%
1.5
US
E
Epizyme Inc
F:EPE
Negative Multiple: -580.7 N/A N/A
AU
CSL Ltd
ASX:CSL
19
11%
1.7
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
12.1
11%
1.1
US
S
Seagen Inc
F:SGT
Negative Multiple: -66.6 N/A N/A
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
US
Inhibikase Therapeutics Inc
NASDAQ:IKT
Average EV/EBIT: 21
Negative Multiple: -1 		N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -192 317.8 N/A N/A
US
Abbvie Inc
NYSE:ABBV
22.7
29%
0.8
US
Cyclo Therapeutics Inc
NASDAQ:CYTH
Negative Multiple: -13 207.5 N/A N/A
US
Amgen Inc
NASDAQ:AMGN
24.4
32%
0.8
US
Gilead Sciences Inc
NASDAQ:GILD
14.5
11%
1.3
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
27.2
17%
1.6
US
E
Epizyme Inc
F:EPE
Negative Multiple: -565.3 N/A N/A
AU
CSL Ltd
ASX:CSL
23.7
14%
1.7
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
13.6
11%
1.2
US
S
Seagen Inc
F:SGT
Negative Multiple: -60.1 N/A N/A

See Also

Summary
IKT intrinsic value, competitors valuation, and company profile.
DCF Valuation
IKT stock valuation using Discount Cash Flow valuation method.
Relative Valuation
IKT stock valuation using valuation multiples.
Wall Street Estimates
IKT price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
IKT stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Back to Top
ALPHA SPREAD
Follow us
Join more than 270,600+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.